Impact of bariatric surgery on the effectiveness of serological response after COVID-19 vaccination - Top-Institutions - MDSpire

Impact of bariatric surgery on the effectiveness of serological response after COVID-19 vaccination

  • By

  • Mohamed Hany

  • Bart Torensma

  • Anwar Ashraf Abouelnasr

  • Ahmed Zidan

  • Mohamed Ibrahim

  • Ann Samy Shafiq Agayby

  • Mohamed Hesham

  • Amel Elsheredy

  • Ghada Ahmed Abu-Sheasha

  • April 29, 2022

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Bariatric Surgery
    • Immunology
    • Infectious Diseases

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Bariatric Surgery
    • Immunology
    • Infectious Diseases

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Bariatric Surgery
    • Immunology
    • Infectious Diseases

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Bariatric Surgery
    • Immunology
    • Infectious Diseases

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Bariatric Surgery
    • Immunology
    • Infectious Diseases

Original Source(s)

Impact of bariatric surgery on the effectiveness of serological response after COVID-19 vaccination

  • by Mohamed Hany, Bart Torensma, Anwar Ashraf Abouelnasr, Ahmed Zidan, Mohamed Ibrahim, Ann Samy Shafiq Agayby, Mohamed Hesham, Amel Elsheredy, Ghada Ahmed Abu-Sheasha

  • April 29, 2022

Related Content

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

Laparoscopic Roux-en-Y Gastric Bypass with the Maestro™ System: a Novel Collaborative Robotic Platform

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.